Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effects of Sarcopenia on Early Postoperative Outcomes in Patients Undergoing Surgical Treatment for Gastric Cancer

13. juni 2020 opdateret af: Ali GUNER, Karadeniz Technical University
We aimed to establish the effects of sarcopenia on postoperative complications among patients undergoing surgical treatment for gastric cancer

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

Among gastrointestinal disease, gastric cancer is a malignancy which is diagnosed predominantly in advanced stages, mostly accompanied with malnutrition when diagnosed, has aggressive behavior with poor oncological outcomes. The only option for curative treatment is surgical resection in this malignancy; however, the surgical procedure itself causes high morbidity and mortality rates. Therefore, physicians combine various treatment modalities and risk assessment to decrease complication and mortality rates.

Sarcopenia is a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life, and death. For the diagnosis of sarcopenia, using the presence of both low muscle mass and decreased muscle function (strength or performance) is recommended. Previous studies showed that colorectal or pancreatic cancer accompanied with sarcopenia has adverse effects on not only for short term and also for long term outcomes. The majority of studies regarding gastric cancer was published from Eastern countries owing to their high incidence. There are few studies from western countries which are mostly retrospective and does not meet the diagnostic criteria of sarcopenia. In the western population, there is no high-quality evidence so far regarding the impact of sarcopenia on early outcomes of gastric cancer surgical treatment.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

185

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Trabzon, Kalkun, 61080
        • Karadeniz Technical University, Faculty of Medicine

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

All consecutive patients undergoing surgery due to gastric cancer will be included in this study.

Beskrivelse

Inclusion Criteria:

  1. Patients undergoing gastric surgery for gastric cancer
  2. Histologically proven gastric adenocarcinoma
  3. Patients over 18 years
  4. Patients who agreed to participate in the study

Exclusion Criteria:

  1. patients treated by non-surgical treatment such as endoscopic treatment, palliative chemotherapy)
  2. patients received palliative surgery without gastric resection (bypass procedures)
  3. patients required thoracotomy/thoracoscopy

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Participants with gastric cancer
All consecutive patients undergoing surgery due to gastric cancer will be included in this study.
No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postoperative complications
Tidsramme: within 30 days after surgery
complications graded by Clavien-Dindo Complication Classification System
within 30 days after surgery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Length of hospital stay
Tidsramme: up to 90 days
time interval from the date of operation to the date of discharge
up to 90 days
Mortality
Tidsramme: within 30 days after surgery
Dying after surgery
within 30 days after surgery
Readmission rate
Tidsramme: within 30 days after surgery
readmission to the hospital because of the adverse events after discharge
within 30 days after surgery
Incidence of sarcopenia
Tidsramme: one day before surgery
Sarcopenia consensus defined by The European Working Group on Sarcopenia in Older People
one day before surgery
Muscle mass volume
Tidsramme: one day before surgery
muscle mass volume of a cross-sectional computerized- tomography image of the L3, corrected for patient height resulting in L3 muscle index.
one day before surgery
Psoas muscle mass volume
Tidsramme: one day before surgery
muscle mass volume of Psoas muscle with 3D reconstruction
one day before surgery
Muscle strength
Tidsramme: one day before surgery
evaluated by handgrip strength test (with digital dynamometer)
one day before surgery
Physical performance
Tidsramme: one day before surgery
evaluated by 4-meter gait speed test
one day before surgery
Major complication
Tidsramme: within 30 days after surgery
grade 3 or higher complications graded by Clavien-Dindo Complication Classification System
within 30 days after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Ali Guner, MD, Karadeniz Technical University Faculty of Medicine

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. december 2016

Primær færdiggørelse (Faktiske)

10. maj 2020

Studieafslutning (Faktiske)

10. juni 2020

Datoer for studieregistrering

Først indsendt

18. maj 2019

Først indsendt, der opfyldte QC-kriterier

20. maj 2019

Først opslået (Faktiske)

21. maj 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. juni 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. juni 2020

Sidst verificeret

1. juni 2020

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner